DSP-0390
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioma, Malignant
Conditions
Glioma, Malignant, Grade II Glioma, IDH Mutation
Trial Timeline
Apr 3, 2025 → May 17, 2026
NCT ID
NCT06636162About DSP-0390
DSP-0390 is a phase 1 stage product being developed by Sumitomo Pharma for Glioma, Malignant. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06636162. Target conditions include Glioma, Malignant, Grade II Glioma, IDH Mutation.
What happened to similar drugs?
0 of 3 similar drugs in Glioma, Malignant were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06636162 | Phase 1 | Recruiting |
| NCT05023551 | Phase 1 | Active |
Competing Products
20 competing products in Glioma, Malignant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Temozolomide | Novocure | Phase 1 | 15 |
| Enzastaurin (LY317615) + Carboplatin | Eli Lilly | Phase 1 | 29 |
| LY2157299 + Lomustine | Eli Lilly | Phase 1 | 29 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 39 |
| DS-1001b | Daiichi Sankyo | Phase 1 | 33 |
| Perampanel + Standard of Care | Eisai | Phase 1/2 | 32 |
| Temozolomide and Bevacizumab | Eisai | Phase 2 | 31 |
| Temozolomide | Eisai | Phase 2 | 31 |
| Gliadel Wafer + Temozolomide | Eisai | Phase 2 | 31 |
| Palonosetron (PALO) | Eisai | Phase 2 | 35 |
| Gliadel/Avastin/CPT-11 | Eisai | Phase 2 | 27 |
| Lenvatinib + Bevacizumab | Eisai | Phase 2 | 35 |
| Granisetron + Ondansetron | Kyowa Kirin | Phase 2 | 27 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 42 |
| Enzastaurin | Eli Lilly | Phase 2 | 35 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 21 |
| LY2157299 + Radiation + Temozolomide | Eli Lilly | Phase 1/2 | 32 |
| Abemaciclib + Temozolomide | Eli Lilly | Phase 2 | 39 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 31 |